Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

669
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
669
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

441
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
441
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

315
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
315
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

368
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
368
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modelling Consent and Data Use Conditions in a Health Data Donation Space.

Studies in health technology and informatics·2026
Same author

European Reference Networks as core health structures where referring genetic newborn screening positive infants: an innovative operational research framework.

Frontiers in public health·2026
Same author

International variation in child healthcare practices and implications for childhood cancer diagnosis: a scoping review and cross-country clinician survey.

European journal of pediatrics·2026
Same author

Privacy-preserving augmentation of structured telehealth activity data in diabetes patients using natural language processing.

Frontiers in digital health·2026
Same author

Physical Activity Prediction for Patients in a Diabetes Telehealth System: Comparison of Different Data Driven Approaches.

Studies in health technology and informatics·2026
Same author

A Fit-Gap Analysis of Care Planning Tools: Evaluating FHIR Compliance.

Studies in health technology and informatics·2026

Related Experiment Video

Updated: Mar 21, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K

Interoperability Architecture for a Paediatric Oncology European Reference Network.

Michael Nitzlnader1, Adela Canete Nieto2, Antonio Juan Ribelles2

  • 1AIT Austrian Institute of Technology GmbH, Austria.

Studies in Health Technology and Informatics
|May 4, 2016
PubMed
Summary

European Reference Networks (ERNs) facilitate cross-border healthcare for rare conditions. The ExPO-r-Net project pilots an ERN for pediatric oncology, detailing use cases, requirements, and an IT architecture for data exchange.

More Related Videos

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

5.4K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 21, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

5.4K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K

Area of Science:

  • Health Policy and Law
  • Health Informatics
  • Oncology

Background:

  • Directive 2011/24/EU established a legal framework for cross-border healthcare within the European Union.
  • Article 12 of the directive supports the development of European Reference Networks (ERNs) for rare and complex medical conditions.
  • The "European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment" (ExPO-r-Net) project pilots an ERN in pediatric oncology.

Purpose of the Study:

  • To describe the high-level use cases for a pediatric oncology ERN.
  • To outline the main requirements for an interoperable IT platform supporting cross-border health data exchange.
  • To present a conceptual interoperability architecture for the ExPO-r-Net project.

Main Methods:

  • Analysis of use cases for cross-border pediatric oncology care.
  • Definition of functional and non-functional requirements for a health data exchange platform.
  • Development of a high-level interoperability architecture.

Main Results:

  • Identified key use cases for specialized pediatric oncology treatment across EU member states.
  • Defined essential requirements for secure and efficient cross-border health data sharing.
  • Proposed an interoperability architecture designed to facilitate data exchange for the ExPO-r-Net.

Conclusions:

  • The ExPO-r-Net project provides a model for establishing ERNs in specialized medical fields like pediatric oncology.
  • A robust IT platform and clear requirements are crucial for successful cross-border healthcare data exchange.
  • ERNs have the potential to improve access to expertise and treatment for rare pediatric cancers across Europe.